Vol.56 No.4 July 2008
Multiple-dose pazufloxacin mesilate pharmacokinetics in patients undergoing maintenance hemodialysis
Department of Pharmacy Service, Shirasagi Hospital, 7-11-23 Kumata, Higashi-Sumiyoshi-ku, Osaka, Japan
Abstract
The multiple-dose pazufloxacin mesilate(PZFX) pharmacokinetics have not been reported in patients with end-stage renal disease(ESRD) undergoing hemodialysis(HD). We intravenously administered a 300 mg dose of PZFX after each HD session in four ESRD patients who required treatment for renal cyst infection , drawing plasma samples to evaluate pharmacokinetic profiles. Cmax after the first dose was 10.47±2.19 μg/mL (mean±SD) and AUC (from zero to infinity) was 421±175 μg· h/mL. PZFX elimination from plasma was markedly delayed compared to that in subjects with normal renal function. After the third dose, the plasma concentration at 2 hours after completing infusion was 11.12±2.30 μg/mL, lower than expected despite impaired total body clearance. Plasma PZFX concentration was markedly decreased by HD and the degrees of removal was calculated at 58.7±7.7% from before HD to just after HD and 45.2±5.9% to 1 hour after completion of HD. Adverse events related to plasma concentration were not reported during treatment. Efficient PZFX removal by regular HD helps to keep excessive plasma concentrations from accumulating and confirms the rationale for administering PZFX after each HD session.
Key word
pazufloxacin, hemodialysis, pharmacokinetics, renal failure
Received
December 17, 2007
Accepted
March 19, 2008
Jpn. J. Chemother. 56 (4): 462-466, 2008
